11/21
09:26 am
nrsn
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND [Yahoo! Finance]
Neutral
Report
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND [Yahoo! Finance]
11/21
09:20 am
nrsn
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
Low
Report
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
10/28
08:30 am
nrsn
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
Medium
Report
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
10/28
08:01 am
nrsn
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission [Yahoo! Finance]
Low
Report
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission [Yahoo! Finance]
10/24
08:30 am
nrsn
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
Medium
Report
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
10/15
09:15 am
nrsn
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
High
Report
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
10/9
09:00 am
nrsn
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
Medium
Report
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
10/7
09:00 am
nrsn
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
Low
Report
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
9/24
09:05 am
nrsn
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
High
Report
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
9/24
09:00 am
nrsn
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
Medium
Report
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
8/30
04:30 pm
nrsn
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
High
Report
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
8/28
07:13 am
nrsn
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug [Yahoo! Finance]
Medium
Report
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug [Yahoo! Finance]